PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Cash & equivalents declining -7.59% while RVPH's grows 369.95%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of RVPH's 369.95%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x RVPH's -19.73%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-8.57%
Below half of RVPH's 339.95%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.56%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Below half of RVPH's 339.95%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-2.42%
Less than half of RVPH's -27.08%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Less than half of RVPH's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
-3.64%
Less than half of RVPH's -94.68%. David Dodd sees fewer expansions in other current obligations.
-2.05%
Less than half of RVPH's 31.78%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of RVPH's -7.64%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of RVPH's 29.30%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Less than half of RVPH's 23.27%. David Dodd sees fewer share issuances vs. competitor.
-2.84%
Below half RVPH's -11.31%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
Below half RVPH's 167.13%. Michael Burry sees potential underperformance in building shareholder capital.
-8.43%
Below half RVPH's 339.95%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.97%
Higher Total Investments Growth compared to RVPH's zero value, indicating better performance.
-4.43%
Less than half of RVPH's -100.00%. David Dodd sees less overall debt expansion vs. competitor.
7.68%
Less than half of RVPH's -391.97%. David Dodd sees better deleveraging or stronger cash buildup than competitor.